Navigation Links
Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease
Date:9/24/2009

"non-culprit" lesions of the three-vessel coronary tree. Half of the patients treated for non-culprit events exemplified the classic notion of vulnerable plaque.

The event rate, particularly that attributed to vulnerable plaques specifically, was lower than expected. Further, patients who experienced "non-culprit" events in the years following PCI were more likely to present with progressive or unstable angina, and rarely with cardiac death, arrest or MI. Imaging of the lesions that did progress to events suggests that vulnerable plaque lesions with a large plaque burden and large necrotic core without a visible cap were at especially high risk for future adverse cardiovascular events.

"Abbott's PROSPECT trial is the most comprehensive study ever done on vulnerable plaque and the results shed new light on understanding its role in the progression of coronary artery disease," said John M. Capek, executive vice president, medical devices, Abbott. "As a leader in cardiovascular devices, diagnostics and medicines, Abbott looks forward to sharing these results with the vascular community and adding to our understanding of the disease."

About the PROSPECT Trial

Abbott's PROSPECT trial is the first prospective natural history study to examine the role of vulnerable plaque and how it might progress to a cardiac event. PROSPECT used novel intravascular imaging technology to correlate plaque characteristics, patient risk factors and biomarker measurements with subsequent heart attacks and other cardiac events, potentially paving the way for physicians to identify and treat at-risk patients before a heart attack occurs.

PROSPECT enrolled 700 patients from 40 clinical centers across the United States and Europe. All patients received PCI for acute coronary syndrome (ACS), which included unstable angina, NSTEMI or STEMI. Patient follow up continued for three years. Abbott sponso
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... on its pipeline and new product development efforts. In ... initiate a Phase 2a study of AZ-002 (Staccato ... the management of patients with acute repetitive seizures. ... -based product candidates for development - AZ-008 and ...
(Date:7/31/2014)... -- UBM Medica US announces that Cancer Network ... exclusive slide shows dealing with communication in the oncology ... Cancer Network, the online home ... and podcasts about the latest clinical findings. Among the ... , End-of-life care is challenging for even the most ...
(Date:7/31/2014)... 31, 2014  Decision Resources Group,s experts ... by the Affordable Care Act (ACA), which ... pharmaceutical therapies. The ACA altered how Managed ... regulations and expanded access via government-supported programs. ... exchanges—state-based marketplaces set up by states or ...
Breaking Medicine Technology:Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4
... Untold Numbers of Consumers Still Left Disabled By Its ... GlaxoSmithKline, the maker of popular denture adhesives Poligrip and Super ... its denture adhesive products.  The pharmaceutical giant has added the potentially ... consuming large quantities of zinc over an extended period of time ...
... , , SHANGHAI , ... WX ), a leading pharmaceutical, biotechnology and medical device R&D outsourcing ... announced that it will release financial results for the fourth quarter of ... 8, 2010 (which will be Tuesday morning, March 9, 2010 ...
Cached Medicine Technology:Leading Denture Cream Litigation Firm Welcomes GSK Announcement of Removal of Zinc From Its Denture Creams 2Leading Denture Cream Litigation Firm Welcomes GSK Announcement of Removal of Zinc From Its Denture Creams 3WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release 2WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release 3
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation (JPML) issued ... strokes, heart attacks, and other injuries in men who ... as the transferee judge and ordered what could be ... , As one of his first organizing acts, Judge ... who will move the litigation forward on behalf of ...
(Date:8/1/2014)... Barbara Bronson Gray HealthDay Reporter ... are obese and work in manufacturing jobs may have significantly less ... In a study of 32 people -- half were obese, half ... endurance times that were about 60 percent longer. Obesity also ... performance. Being older -- 50 to 65 years ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 As it ... behalf of women who allegedly experienced the spread of ... in gynecological surgeries, Bernstein Liebhard LLP notes the growing ... number of power morcellators marketed by its Ethicon, Inc. ... The New York Times, some critics of the company ...
(Date:8/1/2014)... and the benefits of a cancer diagnosis may improve ... a study conducted by a researcher at the University ... an expressive writing intervention is the writing instruction. Otherwise, ... events. Writing a journal can be therapeutic, but oftentimes ... it,s effective or not," said Qian Lu, assistant professor ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 On Monday, ... California NextGen User Symposium in San Francisco, CA. Now ... at the JW Marriott Union Square hotel. , “We ... get up to speed with ACA compliance issues,” Quirk ... month. The symposium provides attendees guidance with NextGen implementation ...
Breaking Medicine News(10 mins):Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2
... obstructive sleep apnea (OSA), a sleep disorder associated with ... coronary arteries, according to a study presented today at ... America (RSNA). "Our study reveals that individuals with ... form of atherosclerosis that puts them at risk for ...
... Using functional magnetic resonance imaging (fMRI), researchers have captured ... stimulus with and without acupuncture to determine acupuncture,s effect ... study, which the researchers say suggest the effectiveness of ... the Radiological Society of North America (RSNA). "Until ...
... Whitehead Institute researchers have shown in mouse models that ... leukemia and accelerate the disease,s progression. Their results are ... of the National Academy of Sciences (PNAS). "MicroRNAs ... mice, can upregulation of a microRNA actually cause the ...
... bottle of pomegranate juice at the store because you,ve learned ... replete with antioxidants that bring health benefits. But wait: ... is the product label you have carefully read promising more ... California, Riverside is determined to find out. Cynthia ...
... MONDAY, Nov. 29 (HealthDay News) -- Women have worse ... (PAD) in their lower extremities, a new study has ... for PAD surgery in lower extremities conducted from 1998 ... Of those hospitalizations, 162,730 (43.6 percent) were women. ...
... News) -- Patients who trust that their doctor would tell ... those who doubt their physician would own up to the ... doesn,t mean patients are less likely to sue. Researchers ... about 40 percent had personal experience with medical errors or ...
Cached Medicine News:Health News:People with sleep apnea at higher risk for aggressive heart disease 2Health News:Acupuncture changes brain's perception and processing of pain 2Health News:Tiny RNA shown to cause multiple types of leukemia 2Health News:Tiny RNA shown to cause multiple types of leukemia 3Health News:How authentic is your pomegranate juice? 2Health News:Peripheral Arterial Surgery Outcomes Worse for Women: Study 2Health News:Trust in Doctor May Affect Reaction to Medical Error 2
Irrigating Cystotome, formed, 23 g., 12 mm curved tip. Overall length 14 mm. 5/box....
Peribulbar Needle, 25 g. Atkinson style bevel. Overall length 31 mm. 5/box....
Scleral Blade tip 5700 style, straight. Dimensions: 15.2 mm (L) x 3.4 mm (W). Cut: 2.7 mm....
Blade tip handle....
Medicine Products: